Ensign Peak Advisors
DCPH

Ensign Peak Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Ensign Peak Advisors’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-22,610
Closed -$418K – 2283
2022
Q3 		$418K Sell
22,610
-17,240
-43% -$271K ﹤0.01% 1549
2022
Q2 		$524K Hold
39,850
– – ﹤0.01% 1439
2022
Q1 		$369K Buy
39,850
+1,670
+4% +$14.2K ﹤0.01% 1678
2021
Q4 		$373K Buy
+38,180
New +$718K ﹤0.01% 1732
2020
Q3 		– Sell
-1,668
Closed -$100K – 1765
2020
Q2 		$100K Hold
1,668
– – ﹤0.01% 1628
2020
Q1 		$69K Buy
+1,668
New +$92.6K ﹤0.01% 1592

Other funds holding DCPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wolverine Trading
Wolverine Trading Chicago, Illinois $139B AUM 31.83% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ensign Peak Advisors's DCPH Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2022, closing a stake of 22,610 shares — an estimated $418K sold.

Ensign Peak Advisors first reported a position in DCPH in Q1 2020 and held it in 6 quarters. The position peaked at $524K in Q2 2022. 143 funds tracked by Wall St. Rank hold DCPH as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 22,610 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $418K.
  • Ensign Peak Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
  • Ensign Peak Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $524K in Q2 2022.
  • 143 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.